modelJ07CA12
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | DiphtheriaPertussisPoliomyelitisTetanusHepatitisB | |
| ATC code: | J07CA12 | route: | intramuscular |
| compartments: | 1 | |
| dosage: | 0.5 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | L/h |
| other parameters in model implementation | ||
This is a combination vaccine used to protect against five serious diseases: diphtheria, pertussis (whooping cough), poliomyelitis, tetanus, and hepatitis B. It is administered primarily to infants and young children as a part of routine immunization schedules. The vaccine is approved and widely used in pediatric practice worldwide.
Pharmacokinetics
No published pharmacokinetic studies or compartmental PK models are available for the pentavalent diphtheria-pertussis-poliomyelitis-tetanus-hepatitis B combination vaccine. The vaccine is typically given as an intramuscular injection in infants and young children; classical pharmacokinetic parameters (such as systemic absorption rates, central volume of distribution, clearance) are not generally relevant or reported for vaccines.
References
Zhu, Q, et al., & Suzich, JA (2017). A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Science translational medicine 9(388) –. DOI:10.1126/scitranslmed.aaj1928 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28469033
Maese, L, et al., & Rau, RE (2023). Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. Blood 141(7) 704–712. DOI:10.1182/blood.2022016923 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36108304
Huang, CJ, et al., & Shih, KC (2023). Pharmacokinetics and Safety of Long-Acting Release Formulations of Pasireotide (SOM230) in a Male Population Who Are Hyperendemic Hepatitis B/C and Chronic Kidney Disease: An Open-Label, Phase I Study. European journal of drug metabolism and pharmacokinetics 48(6) 665–674. DOI:10.1007/s13318-023-00854-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37751056
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)